CD38 and plasma cell myeloma: Multiple studies are underway as aforementioned that combine bispecific antibodies with immunomodulatory drugs, cereblon modulators, anti-CD38 antibodies and PD-1 inhibitions and these therapeutic strategies may mitigate T-cell exhaustion and enhance the efficacy of bispecific antibodies in myeloma.